1. |
11-dehydrocorticosterone
|
regulation of metabolic process
|
Cisplatin
|
[Cisplatin affects regulation of metabolic process] which results in increased abundance of 11-dehydrocorticosterone |
1: Rattus norvegicus |
Kidney
|
|
1 |
2. |
11-dehydrocorticosterone
|
steroid metabolic process
|
Heroin
|
[Heroin affects steroid metabolic process] which results in decreased abundance of 11-dehydrocorticosterone |
1: Mus musculus |
Liver
|
2 genes
|
1 |
3. |
11-fluoro-7-(14,14,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3-5(10)-triene-3,17-diol
|
myotube differentiation
|
Estradiol
|
11-fluoro-7-(14,14,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3-5(10)-triene-3,17-diol inhibits the reaction [Estradiol affects myotube differentiation] |
1: Mus musculus |
Muscle Cells
| Cell Line
|
|
1 |
4. |
11-fluoro-7-(14,14,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3-5(10)-triene-3,17-diol
|
myotube differentiation
|
Albuterol
|
11-fluoro-7-(14,14,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3-5(10)-triene-3,17-diol inhibits the reaction [Albuterol affects myotube differentiation] |
1: Mus musculus |
Muscle Cells
| Cell Line
|
|
1 |
5. |
11-fluoro-7-(14,14,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3-5(10)-triene-3,17-diol
|
myotube differentiation
|
Formoterol Fumarate
|
11-fluoro-7-(14,14,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3-5(10)-triene-3,17-diol inhibits the reaction [Formoterol Fumarate affects myotube differentiation] |
1: Mus musculus |
Muscle Cells
| Cell Line
|
|
1 |
6. |
11-hydroxyprogesterone
|
regulation of metabolic process
|
Soot
|
[Soot affects regulation of metabolic process] which results in decreased abundance of 11-hydroxyprogesterone |
1: Rattus norvegicus |
Serum
|
|
1 |
7. |
11-hydroxyprogesterone 11-glucuronide
|
regulation of cellular metabolic process
|
deoxynivalenol
|
[deoxynivalenol affects regulation of cellular metabolic process] which results in decreased abundance of 11-hydroxyprogesterone 11-glucuronide |
1: Sus scrofa |
Intestinal Mucosa
| Cell Line
|
|
1 |
8. |
11-hydroxytestosterone
|
androgen metabolic process
|
Ketoconazole
|
[Ketoconazole results in decreased androgen metabolic process] which results in decreased chemical synthesis of 11-hydroxytestosterone |
1: Equus caballus |
Microsomes, Liver
|
|
1 |
9. |
11-hydroxytestosterone
|
androgen metabolic process
|
Troleandomycin
|
[Troleandomycin results in decreased androgen metabolic process] which results in decreased chemical synthesis of 11-hydroxytestosterone |
1: Equus caballus |
Microsomes, Liver
|
|
1 |
10. |
11-hydroxytestosterone
|
androgen metabolic process
|
Quercetin
|
[Quercetin results in decreased androgen metabolic process] which results in decreased chemical synthesis of 11-hydroxytestosterone |
1: Equus caballus |
Microsomes, Liver
|
|
1 |
11. |
11-ketotestosterone
|
androgen receptor signaling pathway
|
|
11-ketotestosterone results in increased androgen receptor signaling pathway |
1: Gnathopogon caerulescens |
Sertoli Cells
|
1 gene
|
1 |
12. |
11-ketotestosterone
|
locomotory behavior
|
|
11-ketotestosterone affects locomotory behavior |
1: Danio rerio |
|
|
1 |
13. |
11-ketotestosterone
|
androgen metabolic process
|
bisphenol A
|
[bisphenol A affects androgen metabolic process] which results in increased abundance of 11-ketotestosterone |
1: Gobiocypris rarus |
Tissues
|
1 gene
|
1 |
14. |
11-ketotestosterone
|
steroid biosynthetic process
|
bisphenol A
|
[bisphenol A affects steroid biosynthetic process] which results in decreased abundance of 11-ketotestosterone |
1: Sparus aurata |
Plasma
|
|
1 |
15. |
11-ketotestosterone
|
testosterone biosynthetic process
|
Acetaminophen
|
[Acetaminophen affects testosterone biosynthetic process] which results in decreased abundance of 11-ketotestosterone |
1: Danio rerio |
Testis
|
|
1 |
16. |
11-ketotestosterone
|
negative regulation of androgen secretion
|
bisphenol A
|
[bisphenol A results in increased negative regulation of androgen secretion] which results in decreased secretion of 11-ketotestosterone |
1: Amphiprion ocellaris |
Serum
|
|
1 |
17. |
11-ketotestosterone
|
negative regulation of androgen secretion
|
Ethinyl Estradiol
|
[Ethinyl Estradiol results in increased negative regulation of androgen secretion] which results in decreased abundance of 11-ketotestosterone |
1: Amphiprion ocellaris |
Serum
|
|
1 |
18. |
11-ketotestosterone
|
steroid metabolic process
|
4,4'-hexafluorisopropylidene diphenol
|
[4,4'-hexafluorisopropylidene diphenol affects steroid metabolic process] which results in increased secretion of 11-ketotestosterone |
1: Danio rerio |
Gonads
|
1 gene
|
1 |
19. |
1,23,25-trihydroxyvitamin D3
|
steroid metabolic process
|
sodium arsenate
|
[sodium arsenate affects steroid metabolic process] which results in decreased abundance of 1,23,25-trihydroxyvitamin D3 |
1: Azumapecten farreri |
Gills
|
|
1 |
20. |
1,24,25-trihydroxyvitamin D3
|
cell differentiation
|
|
1,24,25-trihydroxyvitamin D3 results in decreased cell differentiation |
1: Rattus norvegicus |
Skull
| Cells, Cultured
|
1 gene
|
1 |
21. |
1,24,25-trihydroxyvitamin D3
|
cell population proliferation
|
|
1,24,25-trihydroxyvitamin D3 results in increased cell population proliferation |
1: Homo sapiens |
Bone and Bones
| Cells, Cultured
|
|
1 |
22. |
1,24,25-trihydroxyvitamin D3
|
cell population proliferation
|
|
1,24,25-trihydroxyvitamin D3 results in decreased cell population proliferation |
1: Homo sapiens |
Bone and Bones
| Cells, Cultured
|
|
1 |
23. |
1,25,26-trihydroxyvitamin D3
|
cell population proliferation
|
|
1,25,26-trihydroxyvitamin D3 results in decreased cell population proliferation |
1: Homo sapiens |
Bone and Bones
| Cells, Cultured
|
|
1 |
24. |
1,25,26-trihydroxyvitamin D3
|
cell population proliferation
|
|
1,25,26-trihydroxyvitamin D3 results in increased cell population proliferation |
1: Homo sapiens |
Bone and Bones
| Cells, Cultured
|
|
1 |
25. |
1,25-dihydroxy-16-ene-vitamin D3
|
cell population proliferation
|
|
1,25-dihydroxy-16-ene-vitamin D3 results in decreased cell population proliferation |
1: Homo sapiens |
Prostate
| Cell Line, Tumor
|
|
1 |
26. |
1,25-dihydroxy-16-ene-vitamin D3
|
cell cycle
|
|
1,25-dihydroxy-16-ene-vitamin D3 results in decreased cell cycle |
1: Homo sapiens |
HL-60 Cells
|
|
1 |
27. |
1,25-dihydroxy-16-ene-vitamin D3
|
cell differentiation
|
|
1,25-dihydroxy-16-ene-vitamin D3 results in increased cell differentiation |
1: Homo sapiens |
HL-60 Cells
|
1 gene
|
1 |
28. |
1,25-dihydroxy-19-norvitamin D3
|
cell cycle
|
|
1,25-dihydroxy-19-norvitamin D3 analog affects cell cycle |
1: Homo sapiens |
Plasma Cells
|
|
1 |
29. |
1,25-dihydroxy-19-norvitamin D3
|
cell differentiation
|
|
1,25-dihydroxy-19-norvitamin D3 analog affects cell differentiation |
1: Homo sapiens |
Plasma Cells
|
|
1 |
30. |
1,25-dihydroxy-23-oxavitamin D3
|
response to oxidative stress
|
|
1,25-dihydroxy-23-oxavitamin D3 results in increased response to oxidative stress |
1: Homo sapiens |
HL-60 Cells
|
|
1 |
31. |
1,25-dihydroxy-23-thiavitamin D3
|
response to oxidative stress
|
|
1,25-dihydroxy-23-thiavitamin D3 results in increased response to oxidative stress |
1: Homo sapiens |
HL-60 Cells
|
|
1 |
32. |
1,25-dihydroxyergocalciferol
|
xenobiotic metabolic process
|
Ketoconazole
|
[Ketoconazole results in decreased xenobiotic metabolic process] which results in decreased chemical synthesis of 1,25-dihydroxyergocalciferol |
1: Homo sapiens |
Keratinocytes
| Cell Line
|
|
1 |
33. |
1,25-dihydroxyergocalciferol
|
positive regulation of myeloid leukocyte differentiation
|
|
1,25-dihydroxyergocalciferol results in increased positive regulation of myeloid leukocyte differentiation |
1: Homo sapiens |
Myeloid Progenitor Cells
| Cell Line, Tumor
|
|
1 |
34. |
1,25-dihydroxyvitamin D
|
apoptotic process
|
|
1,25-dihydroxyvitamin D results in increased apoptotic process |
1: Mus musculus |
Epithelial Cells
| Cell Line, Tumor
|
5 genes
|
1 |
35. |
1,25-dihydroxyvitamin D
|
cell cycle
|
|
1,25-dihydroxyvitamin D results in decreased cell cycle |
1: Mus musculus |
Epithelial Cells
| Cell Line, Tumor
|
5 genes
|
1 |
36. |
1,25-dihydroxyvitamin D
|
apoptotic process
|
Dexamethasone
|
Dexamethasone promotes the reaction [1,25-dihydroxyvitamin D results in increased apoptotic process] |
1: Mus musculus |
Epithelial Cells
| Cell Line, Tumor
|
5 genes
|
1 |
37. |
1,25-dihydroxyvitamin D
|
cell cycle
|
Dexamethasone
|
Dexamethasone promotes the reaction [1,25-dihydroxyvitamin D results in decreased cell cycle] |
1: Mus musculus |
Epithelial Cells
| Cell Line, Tumor
|
5 genes
|
1 |
38. |
1,25-dihydroxyvitamin D
|
apoptotic process
|
Dexamethasone
| MAPK1
|
[Dexamethasone promotes the reaction [1,25-dihydroxyvitamin D results in decreased activity of MAPK1 protein]] which results in increased apoptotic process |
1: Mus musculus |
Epithelial Cells
| Cell Line, Tumor
|
5 genes
|
1 |
39. |
1,25-dihydroxyvitamin D
|
apoptotic process
|
Dexamethasone
| MAPK3
|
[Dexamethasone promotes the reaction [1,25-dihydroxyvitamin D results in decreased activity of MAPK3 protein]] which results in increased apoptotic process |
1: Mus musculus |
Epithelial Cells
| Cell Line, Tumor
|
5 genes
|
1 |
40. |
1,25-dihydroxyvitamin D
|
cell population proliferation
|
Dexamethasone
| MAPK1
|
[Dexamethasone promotes the reaction [1,25-dihydroxyvitamin D results in decreased activity of MAPK1 protein]] which results in decreased cell population proliferation |
1: Mus musculus |
Epithelial Cells
| Cell Line, Tumor
|
5 genes
|
1 |
41. |
1,25-dihydroxyvitamin D
|
cell population proliferation
|
Dexamethasone
| MAPK3
|
[Dexamethasone promotes the reaction [1,25-dihydroxyvitamin D results in decreased activity of MAPK3 protein]] which results in decreased cell population proliferation |
1: Mus musculus |
Epithelial Cells
| Cell Line, Tumor
|
5 genes
|
1 |
42. |
1,25-dihydroxyvitamin D
|
vitamin D3 metabolic process
|
Cholecalciferol
|
[Cholecalciferol results in increased vitamin D3 metabolic process] which results in increased abundance of 1,25-dihydroxyvitamin D |
1: Homo sapiens |
Serum
|
|
1 |
43. |
1,25-dihydroxyvitamin D
|
positive regulation of T-helper 17 type immune response
|
|
1,25-dihydroxyvitamin D results in increased positive regulation of T-helper 17 type immune response |
1: Homo sapiens |
CD4-Positive T-Lymphocytes
|
|
1 |
44. |
12-ketolithocholic acid
|
regulation of metabolic process
|
Copper Sulfate
|
[Copper Sulfate affects regulation of metabolic process] which results in decreased abundance of 12-ketolithocholic acid |
1: Rattus norvegicus |
Feces
|
|
1 |
45. |
12-ketolithocholic acid
|
bile acid metabolic process
|
Bile Acids and Salts
| tris(chloroethyl)phosphate
|
[[tris(chloroethyl)phosphate affects bile acid metabolic process] which affects the abundance of Bile Acids and Salts] which results in decreased abundance of 12-ketolithocholic acid |
1: Mus musculus |
Liver
|
|
1 |
46. |
12-ketolithocholic acid
|
linoleic acid metabolic process
|
paclobutrazol
|
[paclobutrazol affects linoleic acid metabolic process] which results in decreased abundance of 12-ketolithocholic acid |
1: Rattus norvegicus |
Serum
|
|
1 |
47. |
12-ketolithocholic acid
|
bile acid metabolic process
|
Cholic Acid
|
[Cholic Acid affects bile acid metabolic process] which results in increased abundance of 12-ketolithocholic acid |
1: Rattus norvegicus |
Feces
|
|
1 |
48. |
12-ketolithocholic acid
|
bile acid metabolic process
|
Cholic Acid
|
[Cholic Acid affects bile acid metabolic process] which results in increased abundance of 12-ketolithocholic acid |
1: Rattus norvegicus |
Cecum
| Gastrointestinal Contents
|
|
1 |
49. |
12-ketolithocholic acid
|
bile acid metabolic process
|
Cholic Acid
|
[Cholic Acid affects bile acid metabolic process] which results in increased abundance of 12-ketolithocholic acid |
1: Rattus norvegicus |
Colon
| Gastrointestinal Contents
|
|
1 |
50. |
12-ketolithocholic acid
|
regulation of bile acid metabolic process
|
Methamphetamine
|
[Methamphetamine results in decreased regulation of bile acid metabolic process] which results in decreased abundance of 12-ketolithocholic acid |
1: Mus musculus |
Cecum
|
|
1 |